Solid Biosciences (NASDAQ:SLDB - Free Report) had its target price raised by Chardan Capital from $15.00 to $16.00 in a research note published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Other research analysts have also recently issued reports about the company. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. Wedbush started coverage on Solid Biosciences in a research note on Friday, December 13th. They issued an "outperform" rating and a $16.00 price target on the stock. JMP Securities initiated coverage on Solid Biosciences in a research report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective for the company. Truist Financial assumed coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price objective on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Tuesday, November 12th. Nine research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $15.40.
Check Out Our Latest Report on Solid Biosciences
Solid Biosciences Stock Down 3.7 %
NASDAQ:SLDB traded down $0.22 on Wednesday, hitting $5.78. The stock had a trading volume of 2,182,549 shares, compared to its average volume of 5,248,189. The company has a fifty day moving average price of $3.83 and a two-hundred day moving average price of $5.76. Solid Biosciences has a 1-year low of $2.88 and a 1-year high of $15.05. The stock has a market cap of $234.55 million, a price-to-earnings ratio of -1.90 and a beta of 2.01.
Insider Buying and Selling at Solid Biosciences
In other Solid Biosciences news, CEO Alexander Cumbo sold 11,114 shares of Solid Biosciences stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $62,238.40. Following the transaction, the chief executive officer now directly owns 38,484 shares in the company, valued at approximately $215,510.40. This trade represents a 22.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO David T. Howton sold 5,072 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $28,403.20. Following the completion of the transaction, the chief operating officer now directly owns 15,663 shares in the company, valued at approximately $87,712.80. The trade was a 24.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,069 shares of company stock worth $137,301 over the last three months. Insiders own 13.63% of the company's stock.
Institutional Trading of Solid Biosciences
Several hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Solid Biosciences in the fourth quarter valued at about $34,000. Corton Capital Inc. acquired a new stake in shares of Solid Biosciences in the 4th quarter valued at approximately $41,000. Invesco Ltd. purchased a new stake in shares of Solid Biosciences in the fourth quarter valued at approximately $49,000. Sei Investments Co. acquired a new position in Solid Biosciences during the fourth quarter worth $52,000. Finally, Wells Fargo & Company MN raised its position in Solid Biosciences by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock worth $53,000 after acquiring an additional 2,986 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company's stock.
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
See Also
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
